Pulmonary fibrosis: A possible diabetic complication

Diabetes/Metabolism Research and Reviews

Volumn 27, Issue 4, 2011, Pages 311-317

  Yang, Junling ^a,b   Xue, Qianfei ^c   Miao, Lining ^a   Cai, Lu ^b  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^b University of Louisville School of Medicine   (United States)

^c YANBIAN UNIVERSITY   (China)

Author keywords

Diabetic complications; Diabetic lung fibrosis; Lung oxidative damage; Pulmonary diseases

Indexed keywords

CYTOKINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA1;

CELL PROLIFERATION; CYTOKINE PRODUCTION; DIABETES MELLITUS; FIBROBLAST; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPERGLYCEMIA; INFLAMMATORY INFILTRATE; INSULIN DEPENDENT DIABETES MELLITUS; LUNG ALVEOLUS CELL; LUNG FIBROSIS; LUNG FUNCTION; LUNG FUNCTION TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SPIROMETRY; TOTAL LUNG CAPACITY;

ANIMALS; DIABETES COMPLICATIONS; HUMANS; OXIDATIVE STRESS; PULMONARY FIBROSIS;

EID: 79955705775     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1175     Document Type: Review

References (55)

1. Aleksandrovski YA. Molecular mechanisms of diabetic complications. Biochemistry (Mosc) 1998; 63(11): 1249-1257.
2. Allen DA, Yaqoob MM, Harwood SM. Mechanisms of high glucose-induced apoptosis and its relationship to diabetic complications. J Nutr Biochem 2005; 16(12): 705-713.
3. Ahmad FK, He Z, King GL. Molecular targets of diabetic cardiovascular complications. Curr Drug Targets 2005; 6(4): 487-494.
4. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54(6): 1615-1625.
5. Williams MD, Nadler JL. Inflammatory mechanisms of diabetic complications. Curr Diab Rep 2007; 7(3): 242-248.
6. Sandler M. Is the lung a 'target organ' in diabetes mellitus? Arch Intern Med 1990; 150(7): 1385-1388.
7. van Gent R, Brackel HJ, de Vroede M, van der Ent CK. Lung function abnormalities in children with type I diabetes. Respir Med 2002; 96(12): 976-978.
8. Nicolaie T, Zavoianu C, Nuta P. Pulmonary involvement in diabetes mellitus. Rom J Intern Med 2003; 41(4): 365-374.
9. Kitahara Y, Hattori N, Yokoyama A, et al. The influence of lung function on exercise capacity in patients with type 2 diabetes. Hiroshima J Med Sci 2010; 59(1): 7-13.
10. Cazzato S, Bernardi F, Salardi S, et al. Lung function in children with diabetes mellitus. Pediatr Pulmonol 2004; 37(1): 17-23.
11. Boulbou MS, Gourgoulianis KI, Klisiaris VK, Tsikrikas TS, Stathakis NE, Molyvdas PA. Diabetes mellitus and lung function. Med Princ Pract 2003; 12(2): 87-91.
12. Walton S, Byrd RR, Jr. Fields CL, Ossorio MA, Roy TM. Abnormal pulmonary function and juvenile onset diabetes mellitus. J Ky Med Assoc 1994; 92(3): 101-104.
13. Verrotti A, Verini M, Chiarelli F, Verdesca V, Misticoni G, Morgese G. Pulmonary function in diabetic children with and without persistent microalbuminuria. Diabetes Res Clin Pract 1993; 21(2-3): 171-176.
14. Sandler M, Bunn AE, Stewart RI. Pulmonary function in young insulin-dependent diabetic subjects. Chest 1986; 90(5): 670-675.
15. Mondini S, Guilleminault C. Abnormal breathing patterns during sleep in diabetes. Ann Neurol 1985; 17(4): 391-395.
16. Schuyler MR, Niewoehner DE, Inkley SR, Kohn R. Abnormal lung elasticity in juvenile diabetes mellitus. Am Rev Respir Dis 1976; 113(1): 37-41.
17. Klein OL, Krishnan JA, Glick S, Smith LJ. Systematic review of the association between lung function and Type 2 diabetes mellitus. Diabet Med 2010; 27(9): 977-987.
18. van den Borst B, Gosker HR, Zeegers MP, Schols AM. Pulmonary function in diabetes: a metaanalysis. Chest 2010; 138(2): 393-406.
19. Sime PJ, O'Reilly KM. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol 2001; 99(3): 308-319.
20. Day BJ. Antioxidants as potential therapeutics for lung fibrosis. Antioxid Redox Signal 2008; 10(2): 355-370.
21. Schnack C, Festa A, Schwarzmaier-D'Assie A, Haber P, Schernthaner G. Pulmonary dysfunction in type 1 diabetes in relation to metabolic long-term control and to incipient diabetic nephropathy. Nephron 1996; 74(2): 395-400.
22. Paek YJ, Jung KS, Hwang YI, Lee KS, Lee DR, Lee JU. Association between low pulmonary function and metabolic risk factors in Korean adults: the Korean National Health and Nutrition Survey. Metabolism 2010; 59(9): 1300-1306.
23. Ehrlich SF, Quesenberry CP, Jr. Van Den Eeden SK, Shan J, Ferrara A. Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care 2010; 33(1): 55-60.
24. Vracko R, Thorning D, Huang TW. Basal lamina of alveolar epithelium and capillaries: quantitative changes with aging and in diabetes mellitus. Am Rev Respir Dis 1979; 120(5): 973-983.
25. Weynand B, Jonckheere A, Frans A, Rahier J. Diabetes mellitus induces a thickening of the pulmonary basal lamina. Respiration 1999; 66(1): 14-19.
26. Matsubara T, Hara F. The pulmonary function and histopathological studies of the lung in diabetes mellitus. Nippon Ika Daigaku Zasshi 1991; 58(5): 528-536.
27. Farina J, Furio V, Fernandez-Acenero MJ, Muzas MA. Nodular fibrosis of the lung in diabetes mellitus. Virchows Arch 1995; 427(1): 61-63.
28. Strieter RM, Mehrad B. New mechanisms of pulmonary fibrosis. Chest 2009; 136(5): 1364-1370.
29. Popov D, Hasu M, Costache G, Stern D, Simionescu M. Capillary and aortic endothelia interact in situ with nonenzymatically glycated albumin and develop specific alterations in early experimental diabetes. Acta Diabetol 1997; 34(4): 285-293.
30. Ofulue AF, Thurlbeck WM. Experimental diabetes and the lung. II. In vivo connective tissue metabolism. Am Rev Respir Dis 1988; 138(2): 284-289.
31. Ofulue AF, Kida K, Thurlbeck WM. Experimental diabetes and the lung. I. Changes in growth, morphometry, and biochemistry. Am Rev Respir Dis 1988; 137(1): 162-166.
32. Usuki J, Enomoto T, Azuma A, Matsuda K, Aoyama A, Kudoh S. Influence of hyperglycemia to the severity of pulmonary fibrosis. Chest 2001; 120(Suppl. 1): 71S.
33. Epstein PN, Overbeek PA, Means AR. Calmodulin-induced early-onset diabetes in transgenic mice. Cell 1989; 58(6): 1067-1073.
34. Carlson EC, Audette JL, Veitenheimer NJ, Risan JA, Laturnus DI, Epstein PN. Ultrastructural morphometry of capillary basement membrane thickness in normal and transgenic diabetic mice. Anat Rec A Discov Mol Cell Evol Biol 2003; 271(2): 332-341.
35. Mexas AM, Hess RS, Hawkins EC, Martin LD. Pulmonary lesions in cats with diabetes mellitus. J Vet Intern Med 2006; 20(1): 47-51.
36. Kida K, Utsuyama M, Takizawa T, Thurlbeck WM. Changes in lung morphologic features and elasticity caused by streptozotocin-induced diabetes mellitus in growing rats. Am Rev Respir Dis 1983; 128(1): 125-131.
37. Zheng F, Lu W, Wu F, Li H, Hu X, Zhang F. Recombinant decorin ameliorates the pulmonary structure alterations by down-regulating transforming growth factor-beta1/SMADS signaling in the diabetic rats. Endocr Res 2010; 35(1): 35-49.
38. Cai L, Kang YJ. Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol 2001; 1(3): 181-193.
39. Gumieniczek A, Hopkala H, Wojtowicz Z, Wysocka M. Changes in antioxidant status of lung tissue in experimental diabetes in rabbits. Clin Biochem 2002; 35(2): 147-149.
40. Oztay F, Kandil A, Gurel E, et al. The relationship between nitric oxide and leptin in the lung of rat with streptozotocin-induced diabetes. Cell Biochem Funct 2008; 26(2): 162-171.
41. Di Naso FC, de Mello RN, Bona S, et al. Effect of Agaricus blazei murill on the pulmonary tissue of animals with streptozotocin-induced diabetes. Exp Diabetes Res 2010; 2010: 543926.
42. Schwartz MD, Moore EE, Moore FA, et al. Nuclear factor-kappa B is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Crit Care Med 1996; 24(8): 1285-1292.
43. Eren G, Cukurova Z, Hergunsel O, et al. Protective effect of the nuclear factor kappa B inhibitor pyrrolidine dithiocarbamate in lung injury in rats with streptozotocin-induced diabetes. Respiration 2010; 79(5): 402-410.
44. Kodolova IM, Lysenko LV, Saltykov BB. Changes in the lungs in diabetes mellitus. Arkh Patol 1982; 44(7): 35-40.
45. Aso Y. Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci 2007; 12: 2957-2966.
46. Lee HB, Ha H. Plasminogen activator inhibitor-1 and diabetic nephropathy. Nephrology (Carlton) 2005; 10:(Suppl): S11-13.
47. Oishi K, Ohkura N, Kasamatsu M, et al. Tissue-specific augmentation of circadian PAI-1 expression in mice with streptozotocin-induced diabetes. Thromb Res 2004; 114(2): 129-135.
48. Oishi K, Ohkura N, Ishida N. Adrenal gland-dependent augmentation of plasminogen activator inhibitor-1 expression in streptozotocin-induced diabetic mice. J Thromb Haemost 2006; 4(7): 1566-1574.
49. Ask K, Bonniaud P, Maass K, et al. Progressive pulmonary fibrosis is mediated by TGF-beta isoform 1 but not TGF-beta3. Int J Biochem Cell Biol 2008; 40(3): 484-495.
50. Kanwar YS, Wada J, Sun L, et al. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood) 2008; 233(1): 4-11.
51. Romero JR, Rivera A, Lanca V, Bicho MD, Conlin PR, Ricupero DA. Na + /Ca2+ exchanger activity modulates connective tissue growth factor mRNA expression in transforming growth factor beta1- and Des-Arg10-kallidin-stimulated myofibroblasts. J Biol Chem 2005; 280(15): 14378-14384.
52. Yang JL, Tan Y, Ma ZS, Miao LN, Zhao FL, Cai L. Lung fibrosis in experimental type 1 diabetic mouse model: Role of oxidative stress and inflammation. Diabetes 2010; 59(Suppl. 1): A245.
53. Jang YY, Song JH, Shin YK, Han ES, Lee CS. Protective effect of boldine on oxidative mitochondrial damage in streptozotocin-induced diabetic rats. Pharmacol Res 2000; 42(4): 361-371.
54. Kaneto H, Katakami N, Kawamori D, et al. Involvement of oxidative stress in the pathogenesis of diabetes. Antioxid Redox Signal 2007; 9(3): 355-366.
55. Hsia CC, Raskin P. The diabetic lung: relevance of alveolar microangiopathy for the use of inhaled insulin. Am J Med 2005; 118(3): 205-211.